Extended distribution agreement with Arthrex, Inc.

Tissue Regenix Group PLC

26 November 2024

 

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

CellRight Technologies extends multi-year distribution agreement with Arthrex, Inc.

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that its subsidiary, CellRight Technologies, LLC ("CellRight"), has amended and extended its long-term, multi-year distribution agreement with Arthrex, Inc. ("Arthrex"), a premier innovator of orthopaedic surgical solutions.  

CellRight produces industry leading verified osteobiologics (engineered materials that promote healing of fractures and bone defects) for use in orthopaedic, spine and foot and ankle procedures. The multi-year commitment continues to provide surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes. Arthrex and CellRight entered a marketing and sales agreement in March 2017 and the amendment extends the term until October 2029 where it will renew for additional periods.

Daniel Lee, CEO of Tissue Regenix, commented: "The extension of our long-term distribution agreement will continue to allow physicians and patients access to CellRight's innovative orthobiologics through the Arthrex network. Patient outcomes are positively impacted by orthobiologic products together with the advanced technologies and training from Arthrex. This shared vision is at the core of this strategic partnership."

For more information, please contact:

Tissue Regenix Group plc
Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer	via Walbrook PR
Cavendish Capital Markets (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Edward Whiley Nigel Birks - Life Science Specialist Sales Harriet Ward - ECM	Tel: [phone]
Walbrook PR (Financial PR and IR)	Tel: [phone]
Alice Woodings / Lianne Applegarth	Tissue [e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

END